24_10_Thermo_Channel_banner

THERMO BIOPROCESS ONLINE EVENT SHORTS

17:16 Protecting Biopharma Manufacturing Supply Chains
Protecting Biopharma Manufacturing Supply Chains

In this final segment from the Bioprocess Online Live event, “Protecting Bioprocessing Operations and Supply Chains In A Turbulent Economy,” panelists Adam Golin, Jon Lindbloom, and James Sapirstein share their advice and best practices for sourcing suppliers ...

12:23 Building Resilience In Biomanufacturing Operations
Building Resilience In Biomanufacturing Operations

In this segment from the Bioprocess Online Live event, “Protecting Bioprocessing Operations and Supply Chains In A Turbulent Economy,” panelists share their thoughts on what it means to be resilient and how organizations can embody resilience in their biomanuf...

12:46 How Will U.S. Tariffs And The BIOSECURE Act Impact Global Biopharma Markets?
How Will U.S. Tariffs And The BIOSECURE Act Impact Global Biopharma Markets?

In this segment from the Bioprocess Online Live event, “Protecting Bioprocessing Operations and Supply Chains In A Turbulent Economy,” panelists explain how tariffs imposed by the U.S. are putting competitive pressure on companies to reduce COGs. They also dis...

8:20 Bioprocessing Raw Material And Equipment Costs Are Slow To Recover Post-Pandemic
Bioprocessing Raw Material And Equipment Costs Are Slow To Recover Post-Pandemic

In this segment from the Bioprocess Online Live event, “Protecting Bioprocessing Operations and Supply Chains In A Turbulent Economy,” our panel discusses how the still-high cost of materials and equipment is being factored into manufacturing decisions, as wel...

11:15 How Is U.S. Policy Reshaping Global Biomanufacturing Operations?
How Is U.S. Policy Reshaping Global Biomanufacturing Operations?

In this opening segment from the Bioprocess Online Live event, “Protecting Bioprocessing Operations and Supply Chains In A Turbulent Economy,” panelists Adam Golin, Jon Lindbloom, and James Sapirstein speak candidly about how U.S. tariffs are affecting the glo...

11:32 25_05_BPOL_1280x720_Seg04
Purification Strategies For Multispecifics

In this segment from the Bioprocess Online Live event, “Challenges And Considerations For Purifying Multispecific Molecules,” our panelists Mark Fitchmun and Dr. Jian Ren debate the use of affinity resins compared to ion exchange and multimodal chroma...

8:58 25_05_BPOL_1280x720_Seg01
Characterizing Product- And Process-Related Impurities In Multispecifics

In this segment from the Bioprocess Online Live event, “Challenges And Considerations For Purifying Multispecific Molecules,” our panelists Mark Fitchmun and Dr. Jian Ren examine the types of common impurities manufacturers encounter in multispecific purificat...

6:20 25_05_BPOL_1280x720_Seg05
Strategies For Viral Inactivation And Filtration In Multispecifics

In this segment from the Bioprocess Online Live event, “Challenges And Considerations For Purifying Multispecific Molecules,” our panelists cover molecule sensitivity to low pH and the use of detergent-based viral inactivation, as well as evaluating t...

11:30 25_05_BPOL_1280x720_Seg06
Addressing Manufacturability And Scalability Challenges In Multispecifics Purification

In this final segment from the Bioprocess Online Live event, “Challenges And Considerations For Purifying Multispecific Molecules,” our panelists answer some remaining audience questions relating to viral inactivation, affinity resins, precipitation s...

8:30 25_05_BPOL_1280x720_Seg03
Analytics Are The Eyes Of Process Development

In this segment from the Bioprocess Online Live event, “Challenges And Considerations For Purifying Multispecific Molecules,” panelists Mark Fitchmun and Dr. Jian Ren emphasize the importance of good analytics for your purification strategy.

6:47 25_05_BPOL_1280x720_Seg02
Involve CMC And Formulations Experts Early In Process Development

In this segment from the Bioprocess Online Live event, “Challenges And Considerations For Purifying Multispecific Molecules,” our panelists talk about the cross-functional importance of formulations and CMC leads in process development.

6:59 25_03_BPOL_1280x720_Seg06
Clinical Trial Strategy And ADC Dev Partnership

As the Bioprocess Online Live panel discussion Accelerating ADC Process Development wraps up, expert panelists Dr. Léo Marx (Debiopharm), Dr. Monika Lamba Saini (ADC Therapeutics), and Dr. Philipp Spycher (Araris Biotech) address audience questions on AI-d...

16:27 25_03_BPOL_1280x720_Seg05
ADC Heterogeneity, Site-Specific Conjugation

This busy segment of the Bioprocess Online Live panel discussion Accelerating ADC Process Development finds Dr. Léo Marx (Debiopharm), Dr. Monika Lamba Saini (ADC Therapeutics), and Dr. Philipp Spycher (Araris Biotech) addressing DAR variability and lipoph...

9:37 25_03_BPOL_1280x720_Seg04
Linker And ADC Platform Manufacturing Technologies

In this segment from the Bioprocess Online Live panel discussion Accelerating ADC Process Development, Dr. Léo Marx (Debiopharm) addresses advances in linker technology before he, Dr. Monika Lamba Saini (ADC Therapeutics) and Dr. Philipp Spycher (Araris Bi...

8:59 25_03_BPOL_1280x720_Seg03
Challenges In ADC Process Development

Where does ADC process development fail? In this segment from the Bioprocess Online Live panel discussion Accelerating ADC Process Development, expert panelists Dr. Monika Lamba Saini (ADC Therapeutics), Dr. Léo Marx (Debiopharm), and Dr. Philipp Spycher (...

12:12 25_03_BPOL_1280x720_Seg02
AI In ADC Target Identification

How are AI and machine learning contributing to ADC target identification and early development? Dr. Monika Lamba Saini (ADC Therapeutics), Dr. Léo Marx (Debiopharm), and Dr. Philipp Spycher (Araris Biotech) tackle computational approaches to protein targets, clini...

9:14 25_03_BPOL_1280x720_Seg01
ADCs & Speed To IND

In this opening segment from the Bioprocess Online Live panel discussion Accelerating ADC Process Development, expert panelists Dr. Monika Lamba Saini (ADC Therapeutics), Dr. Léo Marx (Debiopharm), and Dr. Philipp Spycher (Araris Biotech) frame up ADC deve...

12:31 24_08_BPOL_1280x720_Seg08
Outsourcing Considerations For Novel Protein Therapeutics

Panelists discuss special considerations for outsourcing the development and manufacturing of novel, complex protein therapeutics in this Bioprocess Online Live event.

11:13 24_08_BPOL_1280x720_Seg07
Addressing Aggregation And Degradation In Complex Protein Therapeutics

In this segment of the Bioprocess Online Live event Early Process Considerations For Novel Protein Therapeutics, panelists discuss using a transient expression platform to make fast early product attribute decisions.

4:45 24_08_BPOL_1280x720_Seg06
When To Conduct Analytical Assays In Novel Protein Therapeutic Development

Panelists in the Bioprocess Online Live event discuss the various points at which analytical assays are most critical during complex protein therapeutic development.

10:52 24_08_BPOL_1280x720_Seg05
IND Prep Versus Clinical/Commercial Scale-Up In Novel Protein Therapeutics

In this segment of the Bioprocess Online Live event Early Process Considerations For Novel Protein Therapeutics, panelists share detailed considerations for scale-up of complex protein therapeutics.

4:13 24_08_BPOL_1280x720_Seg04
Addressing Post-Translational Modifications In Novel Protein Therapeutics

Meinhard Hasslacher, Ph.D., Head of CMC at SOTIO Biotech, addresses an audience question on conjugation efficiencies in this segment of the Bioprocess Online Live event Early Process Considerations For Novel Protein Therapeutics. From there, we move on to an audience-led ...

7:03 24_08_BPOL_1280x720_Seg03
Key Attributes To Monitor During Cell Line Development Of Complex Proteins

In this segment of the Bioprocess Online Live event Early Process Considerations For Novel Protein Therapeutics, panelists discuss key attributes to monitor during cell line development processes.

8:06 24_08_BPOL_1280x720_Seg02
Cell Line Selection In Novel Protein Therapeutic Development

Lena Tholen, Ph.D., and Meinhard Hasslacher, Ph.D., weigh in early on important cell line selection considerations for novel protein therapeutics in this segment of "Early Process Considerations For Novel Protein Therapeutics".

6:15 24_08_BPOL_1280x720_Seg01
Three Novel Protein Therapeutic Worldviews

In this segment of the Bioprocess Online Live event Early Process Considerations For Novel Protein Therapeutics, we meet panelists who share their topline perspectives on developing complex, novel protein therapeutics.

3:59 24_06_BPOL_1280x720_Seg08
What's Next For Bioprocess Intensification?

Experts speaking on Bioprocess Intensification In The Real World wrap up the Bioprocess Online Live event with parting shots and reflections on the current state of process intensification and what the future holds.

8:56 24_06_BPOL_1280x720_Seg07
Considerations In Continuous Chromatography

In this segment of the Bioprocess Online Live event Bioprocess Intensification In The Real World, our presenters discuss considerations for continuous versus batch chromatography and compare notes on the approaches at their respective organizations.

7:10 24_06_BPOL_1280x720_Seg06
What Analytics Drive Process Intensification?

Bioprocess Online Live panelists discuss the most fundamental analytics that inform and enable process intensification strategies in this segment of Bioprocess Intensification In The Real World.

6:37 24_06_BPOL_1280x720_Seg05
Process Intensification Development Challenges At AZ and AbbVie

In this segment of the Bioprocess Online Live event Bioprocess Intensification In The Real World, panelists respond to audience questions about the challenges they’ve encountered while developing process intensification strategies.

13:33 24_06_BPOL_1280x720_Seg04
Process Intensification Audience Q&A

Our panelists take audience questions on process intensification lessons learned from other industries.